Matthew W. Foehr - Nov 1, 2022 Form 4 Insider Report for OmniAb Operations, Inc. (NONE)

Role
CLO & Secretary, Director
Signature
/s/ Charles S. Berkman, Attorney-in-Fact
Stock symbol
NONE
Transactions as of
Nov 1, 2022
Transactions value $
$0
Form type
4
Date filed
11/3/2022, 09:10 PM
Previous filing
Sep 30, 2022
Next filing
Nov 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NONE Common Stock Award $0 +26.2K +14.07% $0.00 212K Nov 1, 2022 Direct F1, F2, F3
transaction NONE Common Stock Disposed to Issuer -212K -100% 0 Nov 1, 2022 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NONE Stock Option Award $0 +60.9K $0.00 60.9K Nov 1, 2022 Common Stock 60.9K $50.96 Direct F5
transaction NONE Stock Option Disposed to Issuer -60.9K -100% 0 Nov 1, 2022 Common Stock 60.9K $50.96 Direct F4, F5
transaction NONE Stock Option Disposed to Issuer -55.2K -100% 0 Nov 1, 2022 Common Stock 55.2K $41.82 Direct F3, F4, F6
transaction NONE Stock Option Disposed to Issuer -35.3K -100% 0 Nov 1, 2022 Common Stock 35.3K $31.62 Direct F3, F4, F6
transaction NONE Stock Option Disposed to Issuer -22.7K -100% 0 Nov 1, 2022 Common Stock 22.7K $48.21 Direct F3, F4, F6
transaction NONE Stock Option Disposed to Issuer -21.3K -100% 0 Nov 1, 2022 Common Stock 21.3K $56.41 Direct F3, F4, F6
transaction NONE Stock Option Disposed to Issuer -17.7K -100% 0 Nov 1, 2022 Common Stock 17.7K $89.36 Direct F3, F4, F6
transaction NONE Stock Option Disposed to Issuer -29.9K -100% 0 Nov 1, 2022 Common Stock 29.9K $66.30 Direct F3, F4, F7
transaction NONE Stock Option Disposed to Issuer -29K -100% 0 Nov 1, 2022 Common Stock 29K $53.77 Direct F3, F4, F8
transaction NONE Stock Option Disposed to Issuer -11.5K -100% 0 Nov 1, 2022 Common Stock 11.5K $99.75 Direct F3, F4, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Matthew W. Foehr is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2 Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.
F3 Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
F4 Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
F5 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
F6 The stock option is fully vested and exercisable.
F7 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
F8 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
F9 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.